The authors detected low miR-34a levels in MM cells with epigenetic silencing of miR-34a and TP53 mutations while high miR-34a levels were detected in MM cells highly sensitive in vitro to bortezomib. This evidence concerns the gene TP53 and Miyoshi myopathy.